Now showing items 65-84 of 655

    • Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development? 

      Carden, CP; Sarker, D; Postel-Vinay, S; Yap, TA; Attard, G; Banerji, U; Garrett, MD; Thomas, GV; Workman, P; Kaye, SB; de Bono, JS (2010-02)
      Anticancer drug development remains slow, costly and inefficient. One way of addressing this might be the use of predictive biomarkers to select patients for Phase I/II trials. Such biomarkers, which predict response to ...
    • Cancer cell transmission via the placenta. 

      Greaves, M; Hughes, W (2018)
      Cancer cells have a parasitic propensity in the primary host but their capacity to transit between individuals is severely restrained by two factors: a lack of a route for viable cell transfer and immune recognition in ...
    • Cancer genetics, precision prevention and a call to action. 

      Turnbull, C; Sud, A; Houlston, RS (2018-09)
      More than 15 years have passed since the identification, through linkage, of 'first-wave' susceptibility genes for common cancers (BRCA1, BRCA2, MLH1 and MSH2). These genes have strong frequency-penetrance profiles, such ...
    • Cancer-Selective Targeting of the NF-kappa B Survival Pathway with GADD45 beta/MKK7 Inhibitors 

      Morgan, G (2014-10)
      Constitutive NF-B-K signaling promotes survival in multiple myeloma (MM) and other cancers; however, current NF-B-K-targeting strategies lack cancer cell specificity. Here, we identify the interaction between the ...
    • CancerGD: A Resource for Identifying and Interpreting Genetic Dependencies in Cancer. 

      Bridgett, S; Campbell, J; Lord, CJ; Ryan, CJ (2017-07-26)
      Genes whose function is selectively essential in the presence of cancer-associated genetic aberrations represent promising targets for the development of precision therapeutics. Here, we present CancerGD, a resource that ...
    • Candidate gene association studies and risk of Hodgkin lymphoma: a systematic review and meta-analysis. 

      Sud, A; Hemminki, K; Houlston, RS (2015-06-05)
      To evaluate the contribution of association studies of candidate polymorphisms to inherited predisposition to Hodgkin lymphoma (HL), we conducted a systematic review and meta-analysis of published case-control studies. Of ...
    • CanVar: A resource for sharing germline variation in cancer patients. 

      Chubb, D; Broderick, P; Dobbins, SE; Houlston, RS (2016)
      The advent of high-throughput sequencing has accelerated our ability to discover genes predisposing to disease and is transforming clinical genomic sequencing. In both contexts knowledge of the spectrum and frequency of ...
    • Capture Hi-C identifies putative target genes at 33 breast cancer risk loci. 

      Baxter, JS; Leavy, OC; Dryden, NH; Maguire, S; Johnson, N; Fedele, V; Simigdala, N; Martin, L-A; Andrews, S; Wingett, SW; Assiotis, I; Fenwick, K; Chauhan, R; Rust, AG; Orr, N; Dudbridge, F; Haider, S; Fletcher, O (2018-03-12)
      Genome-wide association studies (GWAS) have identified approximately 100 breast cancer risk loci. Translating these findings into a greater understanding of the mechanisms that influence disease risk requires identification ...
    • Capture Hi-C Library Generation and Analysis to Detect Chromatin Interactions. 

      Orlando, G; Kinnersley, B; Houlston, RS (2018-07-06)
      Chromosome conformation capture (3C), coupled with next-generation sequencing (Hi-C), provides a means for deciphering not only the principles underlying genome folding and architecture, but more broadly, the role 3D ...
    • Carbon dating cancer: defining the chronology of metastatic progression in a colorectal cancer case 

      Lote, H; Spiteri, I; Ermini, L; Vatsiou, A; Roy, A; McDonald, A; Maka, N; Balsitis, M; Bose, N; Simbolo, M; Mafficin, A; Lampis, A; Hahne, JC; Trevisani, F; Eltahir, Z; Mentrasti, G; Findlay, C; Kalkman, EAJ; Punta, M; Werner, B; Lise, S; Aktipis, A; Maley, C; Greaves, M; Braconi, C; White, J; Fassan, M; Scarpa, A; Sottoriva, A; Valeri, N
    • Carbon dating cancer: defining the chronology of metastatic progression in colorectal cancer. 

      Lote, H; Spiteri, I; Ermini, L; Vatsiou, A; Roy, A; McDonald, A; Maka, N; Balsitis, M; Bose, N; Simbolo, M; Mafficini, A; Lampis, A; Hahne, JC; Trevisani, F; Eltahir, Z; Mentrasti, G; Findlay, C; Kalkman, EAJ; Punta, M; Werner, B; Lise, S; Aktipis, A; Maley, C; Greaves, M; Braconi, C; White, J; Fassan, M; Scarpa, A; Sottoriva, A; Valeri, N
      Background: Patients often ask oncologists how long a cancer has been present before causing symptoms or spreading to other organs. The evolutionary trajectory of cancers can be defined using phylogenetic approaches but ...
    • Carbon dating cancer: defining the chronology of metastatic progression in colorectal cancer. 

      Lote, H; Spiteri, I; Ermini, L; Vatsiou, A; Roy, A; McDonald, A; Maka, N; Balsitis, M; Bose, N; Simbolo, M; Mafficini, A; Lampis, A; Hahne, JC; Trevisani, F; Eltahir, Z; Mentrasti, G; Findlay, C; Kalkman, EAJ; Punta, M; Werner, B; Lise, S; Aktipis, A; Maley, C; Greaves, M; Braconi, C; White, J; Fassan, M; Scarpa, A; Sottoriva, A; Valeri, N (2017-06-01)
      Background: Patients often ask oncologists how long a cancer has been present before causing symptoms or spreading to other organs. The evolutionary trajectory of cancers can be defined using phylogenetic approaches but ...
    • Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. 

      Tutt, A; Tovey, H; Cheang, MCU; Kernaghan, S; Kilburn, L; Gazinska, P; Owen, J; Abraham, J; Barrett, S; Barrett-Lee, P; Brown, R; Chan, S; Dowsett, M; Flanagan, JM; Fox, L; Grigoriadis, A; Gutin, A; Harper-Wynne, C; Hatton, MQ; Hoadley, KA; Parikh, J; Parker, P; Perou, CM; Roylance, R; Shah, V; Shaw, A; Smith, IE; Timms, KM; Wardley, AM; Wilson, G; Gillett, C; Lanchbury, JS; Ashworth, A; Rahman, N; Harries, M; Ellis, P; Pinder, SE; Bliss, JM (2018-05)
      Germline mutations in BRCA1/2 predispose individuals to breast cancer (termed germline-mutated BRCA1/2 breast cancer, gBRCA-BC) by impairing homologous recombination (HR) and causing genomic instability. HR also repairs ...
    • Carcinogenic polycyclic aromatic hydrocarbons induce CYP1A1 in human cells via a p53-dependent mechanism 

      Wohak, Laura (2016)
      The tumour suppressor gene TP53 is mutated in more than 50 % of human tumours, making it one of the most important cancer genes. We have investigated the role of TP53 in cytochrome P450 (CYP)-mediated metabolic activation ...
    • CardioClassifier: disease- and gene-specific computational decision support for clinical genome interpretation. 

      Whiffin, N; Walsh, R; Govind, R; Edwards, M; Ahmad, M; Zhang, X; Tayal, U; Buchan, R; Midwinter, W; Wilk, AE; Najgebauer, H; Francis, C; Wilkinson, S; Monk, T; Brett, L; O'Regan, DP; Prasad, SK; Morris-Rosendahl, DJ; Barton, PJR; Edwards, E; Ware, JS; Cook, SA (2018-10)
      PURPOSE: Internationally adopted variant interpretation guidelines from the American College of Medical Genetics and Genomics (ACMG) are generic and require disease-specific refinement. Here we developed CardioClassifier ...
    • Case 33. Diagnostic difficulty in a patient with acute leukemia 

      Tso, ACY; Olavarria, E; Matutes, E; Bain, BJ (Taylor & Francis, 2007-01-01)
    • Case 35: An unusual haematological neoplasm characterized by cells with cytoplasmic tails 

      Morilla, Ricardo (2007-06)
      A middle aged Northern European man presented with a submental lymph node and was found on imaging to have generalized lymphadenopathy. There was bone marrow infiltration by small apparently lymphoid cells, many with ...
    • Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses. 

      Lorente, D; Omlin, A; Zafeiriou, Z; Nava-Rodrigues, D; Pérez-López, R; Pezaro, C; Mehra, N; Sheridan, E; Figueiredo, I; Riisnaes, R; Miranda, S; Crespo, M; Flohr, P; Mateo, J; Altavilla, A; Ferraldeschi, R; Bianchini, D; Attard, G; Tunariu, N; de Bono, J (2016-05-05)
      The urgent need for castration-resistant prostate cancer molecular characterization to guide treatment has been constrained by the disease's predilection to metastasize primarily to bone. We hypothesized that the use of ...
    • Catalytic inhibition of KDM1A in Ewing sarcoma is insufficient as a therapeutic strategy. 

      Romo-Morales, A; Aladowicz, E; Blagg, J; Gatz, SA; Shipley, JM (2019-09)
      BACKGROUND: Ewing sarcoma and desmoplastic small round cell tumors (DSRCT) are rare and clinically aggressive sarcomas usually characterized by oncogenic fusion proteins involving EWS. Emerging studies of Ewing sarcoma ...
    • Catch my drift? Making sense of genomic intra-tumour heterogeneity. 

      Sottoriva, A; Barnes, CP; Graham, TA (2017-04)
      The cancer genome is shaped by three components of the evolutionary process: mutation, selection and drift. While many studies have focused on the first two components, the role of drift in cancer evolution has received ...